Skip to content
Menu

Head-to-head comparison

CoreAge Rx vs VyrarX

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #1Desk pick
CoreAge Rx

One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

$99/mo (12-month prepay) sema · $149/mo (12-month prepay) tirz · Verified August 2026

Marked down on: The advertised $99/$149 per month is a 12-month plan paid in full ($1,188 / $1,788 up front); no month-to-month price is published

vs
Ranked #97
VyrarX

VyrarX is a LegitScript-certified telehealth platform offering compounded semaglutide (from $179/month) and compounded tirzepatide (from $329/month) via weekly injection, with provider messaging and nutrition coaching included — and no ladder published behind either "from".

From $179/mo sema · From $329/mo tirz · Verified August 2026

Marked down on: Both prices are "from" figures with nothing behind them — no ladder, no dose banding, no plan lengths — on a site whose own badge reads "Transparent pricing"

CoreAge Rx takes this head-to-head with the higher Desk Score, 94/100 (A) against 78/100 (C+) for VyrarX. VyrarX still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

CoreAge Rx

94/100

A

Overall

VyrarX

78/100

C+

Price transparency

96
78

State access

98
78

Molecule range

90
66

Onboarding speed

92
82

Support responsiveness

93
88

Licensing & trust

94
79

The spec sheet

FieldCoreAge RxVyrarX
Semaglutide$99/mo12-month prepay$99/mo only as a 12-month plan paid in full ($1,188 in one charge); the lander says "starting at, based on a 12-month plan paid in full"; no month-to-month price is published; same price at every dose; compounded injectableFrom $179/moFrom $179/mo (compounded; the site publishes no ladder, dose banding or term behind the word "from")
Tirzepatide$149/mo12-month prepay$149/mo only as a 12-month plan paid in full ($1,788 in one charge); no month-to-month price is published; same price at every dose; compounded injectableFrom $329/moFrom $329/mo (compounded; the site publishes no ladder, dose banding or term behind the word "from")
CoverageAll 50 states47 states (not California, South Carolina or New Jersey)
Brand-nameCompounded onlyCompounded only
Oral optionInjectable onlyInjectable only
Best forAnyone who can prepay a year and wants one dose-independent price with full nationwide reach.Readers outside California, South Carolina and New Jersey who want provider messaging and nutrition coaching bundled in, and will complete a five-minute intake to learn what the price becomes at their dose.
Desk Score94/100A78/100C+

The verdict

Desk pick — CoreAge Rx

CoreAge Rx takes this head-to-head with the higher Desk Score, 94/100 (A) against 78/100 (C+) for VyrarX. VyrarX still holds its ground where its strengths line up with yours.

Choose CoreAge Rx if…

Anyone who can prepay a year and wants one dose-independent price with full nationwide reach.

$99/mo (12-month prepay) sema · $149/mo (12-month prepay) tirz · All 50 states

Choose VyrarX if…

Readers outside California, South Carolina and New Jersey who want provider messaging and nutrition coaching bundled in, and will complete a five-minute intake to learn what the price becomes at their dose.

From $179/mo sema · From $329/mo tirz · 47 states (not California, South Carolina or New Jersey)

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: CoreAge Rx · VyrarX.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.